T1	Participants 79 93	healthy adults
T2	Participants 558 628	at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
T3	Participants 630 661	Participants (aged 18-65 years)
T4	Participants 1577 1812	Between Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20)
